Abstract
The COVID-19 pandemic has raised concerns about antimicrobial resistance (AMR), especially in the context of secondary bacterial infections. This study investigates the impact of SARS-CoV-2 infection on the resistome of the upper respiratory tract (URT) using a metagenomic next-generation sequencing (mNGS) approach. Samples from 48 SARS-CoV-2-infected individuals and 47 healthy individuals from Central India were analyzed to assess variations in AMR gene profiles. Our results revealed significant differences in AMR gene diversity and abundance between the two groups. SARS-CoV-2 samples exhibited greater alpha diversity (Chao1 index) and higher variability, as evidenced by PCA and PCoA analyses, which showed distinct clustering. Additionally, 24 AMR gene families were significantly more abundant in the SARS-CoV-2 group. These gene families conferred resistance against 20 different drug classes, including macrolides, beta-lactams, and aminoglycosides. Notably, AMR genes linked to ESKAPE pathogens were more prevalent in the SARS-CoV-2 group. These findings highlight the potential role of SARS-CoV-2 in driving changes in the URT resistome, with implications for managing secondary infections and guiding antibiotic stewardship in future pandemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors are thankful to CSIR-NEERI for providing funds under project OLP-57 (March 2023 -April 2024) for conducting this study This manuscript has obtained the approval of the Knowledge Resource Center (KRC) publication committee of CSIR-NEERI (KRC No.: CSIR-NEERI/KRC/2024/NOV/EEPM/1) Date: 14-11-2024
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethics Committee for Research on Human Subjects (IEC) of CSIR-NEERI, Nagpur-20, India.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
The data is available as supplementary data with the file name “combined_supplementary_data” Any additional data, if required, will be made available on request by the authors.
